Daily Stock Analysis, AGN, Allergan plc, priceseries

Allergan plc. Daily Stock Analysis
Stock Information
Open
166.28
Close
166.47
High
167.29
Low
165.42
Previous Close
165.73
Daily Price Gain
0.74
YTD High
169.40
YTD High Date
Jul 2, 2019
YTD Low
113.74
YTD Low Date
Jun 17, 2019
YTD Price Change
32.64
YTD Gain
24.39%
52 Week High
193.20
52 Week High Date
Oct 3, 2018
52 Week Low
113.74
52 Week Low Date
Jun 17, 2019
52 Week Price Change
-21.15
52 Week Gain
-11.27%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 21. 2016
185.38
Jan 12. 2017
202.83
14 Trading Days
9.41%
Link
LONG
Jan 31. 2017
209.18
Feb 28. 2017
234.75
19 Trading Days
12.23%
Link
LONG
Jun 6. 2018
151.79
Jun 25. 2018
167.43
13 Trading Days
10.30%
Link
LONG
Jul 25. 2018
172.74
Aug 23. 2018
183.18
21 Trading Days
6.04%
Link
LONG
Mar 7. 2019
141.59
Mar 22. 2019
148.80
11 Trading Days
5.09%
Link
Company Information
Stock Symbol
AGN
Exchange
NYSE
Company URL
http://www.allergan.com
Company Phone
(216) 523-5000
CEO
Brenton L. Saunders
Headquarters
California
Business Address
CLONSHAUGH BUSINESS AND TECHNOLOGY PARK, COOLOCK, DUBLIN, IRELAND D17 E400
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001578845
About

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded on in 1984 and is headquartered in Dublin, Ireland.

Description

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.